Last reviewed · How we verify
FASUDIL
At a glance
| Generic name | FASUDIL |
|---|---|
| Drug class | fasudil |
| Target | Rho-associated protein kinase 2 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Cerebral ischemia
- Spasm of cerebral arteries
Common side effects
Key clinical trials
- Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (PHASE2)
- A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer (PHASE2)
- Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer (PHASE2,PHASE3)
- Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) (PHASE2)
- A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer (PHASE2)
- Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) (PHASE2)
- Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS (PHASE2)
- Fasudil fOr redUcing elopemeNt and Spatial Disorientation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FASUDIL CI brief — competitive landscape report
- FASUDIL updates RSS · CI watch RSS